{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:01:26Z","timestamp":1791907286295,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Idiopathic normal pressure hydrocephalus (iNPH) is characterized by reversible neurological symptoms due to an impairment in cerebrospinal fluid (CSF) clearance. In these patients, cognitive functions are severely impaired, with a scenario similar to Alzheimer\u2019s disease (AD), making the differential diagnosis difficult and highlighting the need of new markers. We analyzed the composition of sphingolipids (SLs) in serum, by combining a single phase extraction with a high-performance thin-layer chromatography (HPTLC) primuline-profiling, and, in CSF, by MALDI profiling and LC-MS. Ceramides and sphingomyelins (SMs) were similar in serum of iNPH and AD patients compared to healthy controls, whereas, in CSF, MALDI profiling indicated that: 1) SM C24:1 is significantly decreased in AD compared to iNPH patients and controls (Kruskal-Wallis p-value\u2009&lt;\u20090.00001); 2) phosphatidylcholine (PC) 36:2 is increased in iNPH patients (p-value\u2009&lt;\u20090.001). LC-MS identified an increasing trend of Cer C24:0 and of a set of SMs in patients with AD, a significant decrease of sphingosine-1-phosphate (S1P) (t-test p-value 0.0325) and an increase of glucosylceramide (GlcCer) C24:0 (p-value 0.0037) in AD compared to iNPH patients. In conclusion CSF PC 36:2, SM C24:1, S1P, and GlcCer can contribute to improve the differential diagnosis of patients with iNPH or AD and foster preventive therapeutic strategies in the early phase of the disease.<\/jats:p>","DOI":"10.1038\/s41598-018-31756-0","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T14:10:28Z","timestamp":1536156628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Particular CSF sphingolipid patterns identify iNPH and AD patients"],"prefix":"10.1038","volume":"8","author":[{"given":"Enrica","family":"Torretta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Arosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Barbacini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Casati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2996-6912","authenticated-orcid":false,"given":"Cecilia","family":"Gelfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"31756_CR1","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1001\/archneur.60.8.1119","volume":"60","author":"LE Hebert","year":"2003","unstructured":"Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A. & Evans, D. A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Archives of neurology 60, 1119\u20131122, https:\/\/doi.org\/10.1001\/archneur.60.8.1119 (2003).","journal-title":"Archives of neurology"},{"key":"31756_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer\u2019s disease. Lancet 368, 387\u2013403, https:\/\/doi.org\/10.1016\/S0140-6736(06)69113-7 (2006).","journal-title":"Lancet"},{"key":"31756_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow, K. & Hampel, H. CSF markers for incipient Alzheimer\u2019s disease. The Lancet. Neurology 2, 605\u2013613 (2003).","journal-title":"The Lancet. Neurology"},{"key":"31756_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature reviews. Neurology 6, 131\u2013144, https:\/\/doi.org\/10.1038\/nrneurol.2010.4 (2010).","journal-title":"Nature reviews. Neurology"},{"key":"31756_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. The Lancet. Neurology 15, 673\u2013684, https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3 (2016).","journal-title":"The Lancet. Neurology"},{"key":"31756_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3233\/JAD-130581","volume":"38","author":"A Di Ieva","year":"2014","unstructured":"Di Ieva, A., Valli, M. & Cusimano, M. D. Distinguishing Alzheimer\u2019s disease from normal pressure hydrocephalus: a search for MRI biomarkers. Journal of Alzheimer\u2019s disease: JAD 38, 331\u2013350, https:\/\/doi.org\/10.3233\/JAD-130581 (2014).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"31756_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3233\/JAD-2010-1406","volume":"20","author":"BR Ott","year":"2010","unstructured":"Ott, B. R. et al. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer\u2019s disease. Journal of Alzheimer\u2019s disease: JAD 20, 647\u2013657, https:\/\/doi.org\/10.3233\/JAD-2010-1406 (2010).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"31756_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JAD-142622","volume":"45","author":"N Jingami","year":"2015","unstructured":"Jingami, N. et al. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer\u2019s disease. Journal of Alzheimer\u2019s disease: JAD 45, 109\u2013115, https:\/\/doi.org\/10.3233\/JAD-142622 (2015).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"31756_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0022-510X(65)90016-X","volume":"2","author":"S Hakim","year":"1965","unstructured":"Hakim, S. & Adams, R. D. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. Journal of the neurological sciences 2, 307\u2013327 (1965).","journal-title":"Journal of the neurological sciences"},{"key":"31756_CR10","doi-asserted-by":"crossref","unstructured":"Relkin, N., Marmarou, A., Klinge, P., Bergsneider, M. & Black, P. M. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 57, S4\u201316; discussion ii-v (2005).","DOI":"10.1227\/01.NEU.0000168185.29659.C5"},{"key":"31756_CR11","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/jnnp.68.6.778","volume":"68","author":"J Golomb","year":"2000","unstructured":"Golomb, J. et al. Alzheimer\u2019s disease comorbidity in normal pressure hydrocephalus: prevalence and shunt respons. e. Journal of neurology, neurosurgery, and psychiatry 68, 778\u2013781 (2000).","journal-title":"e. Journal of neurology, neurosurgery, and psychiatry"},{"key":"31756_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s007010050386","volume":"141","author":"S Savolainen","year":"1999","unstructured":"Savolainen, S., Paljarvi, L. & Vapalahti, M. Prevalence of Alzheimer\u2019s disease in patients investigated for presumed normal pressure hydrocephalus: a clinical and neuropathological study. Acta neurochirurgica 141, 849\u2013853 (1999).","journal-title":"Acta neurochirurgica"},{"key":"31756_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/brain\/awh178","volume":"127","author":"GD Silverberg","year":"2004","unstructured":"Silverberg, G. D. Normal pressure hydrocephalus (NPH): ischaemia, CSF stagnation or both. Brain: a journal of neurology 127, 947\u2013948, https:\/\/doi.org\/10.1093\/brain\/awh178 (2004).","journal-title":"Brain: a journal of neurology"},{"key":"31756_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ana.22015","volume":"68","author":"R Hamilton","year":"2010","unstructured":"Hamilton, R. et al. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Annals of neurology 68, 535\u2013540, https:\/\/doi.org\/10.1002\/ana.22015 (2010).","journal-title":"Annals of neurology"},{"key":"31756_CR15","doi-asserted-by":"publisher","first-page":"312526","DOI":"10.4061\/2011\/312526","volume":"2011","author":"V Leinonen","year":"2011","unstructured":"Leinonen, V. et al. Cerebrospinal fluid biomarkers in idiopathic normal pressure hydrocephalus. International journal of Alzheimer\u2019s disease 2011, 312526, https:\/\/doi.org\/10.4061\/2011\/312526 (2011).","journal-title":"International journal of Alzheimer\u2019s disease"},{"key":"31756_CR16","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1212\/WNL.0000000000000916","volume":"83","author":"NR Graff-Radford","year":"2014","unstructured":"Graff-Radford, N. R. Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus. Neurology 83, 1573\u20131575, https:\/\/doi.org\/10.1212\/WNL.0000000000000916 (2014).","journal-title":"Neurology"},{"key":"31756_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1046\/j.1440-1819.2000.00658.x","volume":"54","author":"T Kudo","year":"2000","unstructured":"Kudo, T. et al. Tau protein is a potential biological marker for normal pressure hydrocephalus. Psychiatry and clinical neurosciences 54, 199\u2013202, https:\/\/doi.org\/10.1046\/j.1440-1819.2000.00658.x (2000).","journal-title":"Psychiatry and clinical neurosciences"},{"key":"31756_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00702-003-0075-x","volume":"111","author":"H Lins","year":"2004","unstructured":"Lins, H. et al. Immunoreactivities of amyloid beta peptide((1\u201342)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. J Neural Transm (Vienna) 111, 273\u2013280, https:\/\/doi.org\/10.1007\/s00702-003-0075-x (2004).","journal-title":"J Neural Transm (Vienna)"},{"key":"31756_CR19","doi-asserted-by":"publisher","unstructured":"Tsai, A., Malek-Ahmadi, M., Kahlon, V. & Sabbagh, M. N. Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer\u2019s Disease. Journal of Alzheimer\u2019s disease & Parkinsonism 4, https:\/\/doi.org\/10.4172\/2161-0460.1000150 (2014).","DOI":"10.4172\/2161-0460.1000150"},{"key":"31756_CR20","doi-asserted-by":"crossref","unstructured":"Hebb, A. O. & Cusimano, M. D. Idiopathic normal pressure hydrocephalus: a systematic review of diagnosis and outcome. Neurosurgery 49, 1166\u20131184; discussion 1184\u20131166 (2001).","DOI":"10.1227\/00006123-200111000-00028"},{"key":"31756_CR21","doi-asserted-by":"publisher","first-page":"e0179280","DOI":"10.1371\/journal.pone.0179280","volume":"12","author":"C Fania","year":"2017","unstructured":"Fania, C. et al. Protein signature in cerebrospinal fluid and serum of Alzheimer\u2019s disease patients: The case of apolipoprotein A-1 proteoforms. PloS one 12, e0179280, https:\/\/doi.org\/10.1371\/journal.pone.0179280 (2017).","journal-title":"PloS one"},{"key":"31756_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-141899","volume":"46","author":"B Ellis","year":"2015","unstructured":"Ellis, B., Hye, A. & Snowden, S. G. Metabolic Modifications in Human Biofluids Suggest the Involvement of Sphingolipid, Antioxidant, and Glutamate Metabolism in Alzheimer\u2019s Disease Pathogenesi. s. Journal of Alzheimer\u2019s disease: JAD 46, 313\u2013327, https:\/\/doi.org\/10.3233\/JAD-141899 (2015).","journal-title":"s. Journal of Alzheimer\u2019s disease: JAD"},{"key":"31756_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/YCO.0000000000000303","volume":"30","author":"MW Wong","year":"2017","unstructured":"Wong, M. W., Braidy, N., Poljak, A. & Sachdev, P. S. The application of lipidomics to biomarker research and pathomechanisms in Alzheimer\u2019s disease. Current opinion in psychiatry 30, 136\u2013144, https:\/\/doi.org\/10.1097\/YCO.0000000000000303 (2017).","journal-title":"Current opinion in psychiatry"},{"key":"31756_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1194\/jlr.M046672","volume":"55","author":"S Bergante","year":"2014","unstructured":"Bergante, S. et al. Gangliosides as a potential new class of stem cell markers: the case of GD1a in human bone marrow mesenchymal stem cells. Journal of lipid research 55, 549\u2013560, https:\/\/doi.org\/10.1194\/jlr.M046672 (2014).","journal-title":"Journal of lipid research"},{"key":"31756_CR25","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1194\/jlr.M200241-JLR200","volume":"43","author":"LA Cowart","year":"2002","unstructured":"Cowart, L. A., Szulc, Z., Bielawska, A. & Hannun, Y. A. Structural determinants of sphingolipid recognition by commercially available anti-ceramide antibodies. Journal of lipid research 43, 2042\u20132048 (2002).","journal-title":"Journal of lipid research"},{"key":"31756_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12017-010-8121-y","volume":"12","author":"MM Mielke","year":"2010","unstructured":"Mielke, M. M. & Lyketsos, C. G. Alterations of the sphingolipid pathway in Alzheimer\u2019s disease: new biomarkers and treatment targets? Neuromolecular medicine 12, 331\u2013340, https:\/\/doi.org\/10.1007\/s12017-010-8121-y (2010).","journal-title":"Neuromolecular medicine"},{"key":"31756_CR27","doi-asserted-by":"publisher","first-page":"e0125597","DOI":"10.1371\/journal.pone.0125597","volume":"10","author":"AN Fonteh","year":"2015","unstructured":"Fonteh, A. N. et al. Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer\u2019s disease. PloS one 10, e0125597, https:\/\/doi.org\/10.1371\/journal.pone.0125597 (2015).","journal-title":"PloS one"},{"key":"31756_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.neulet.2012.04.019","volume":"516","author":"M Kosicek","year":"2012","unstructured":"Kosicek, M., Zetterberg, H., Andreasen, N., Peter-Katalinic, J. & Hecimovic, S. Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer\u2019s disease. Neuroscience letters 516, 302\u2013305, https:\/\/doi.org\/10.1016\/j.neulet.2012.04.019 (2012).","journal-title":"Neuroscience letters"},{"key":"31756_CR29","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1016\/j.neurobiolaging.2014.05.019","volume":"35","author":"MM Mielke","year":"2014","unstructured":"Mielke, M. M. et al. Cerebrospinal fluid sphingolipids, beta-amyloid, and tau in adults at risk for Alzheimer\u2019s disease. Neurobiology of aging 35, 2486\u20132494, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.05.019 (2014).","journal-title":"Neurobiology of aging"},{"key":"31756_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00002093-199601020-00004","volume":"10","author":"CG Gottfries","year":"1996","unstructured":"Gottfries, C. G., Jungbjer, B., Karlsson, I. & Svennerholm, L. Reductions in membrane proteins and lipids in basal ganglia of classic Alzheimer disease patients. Alzheimer disease and associated disorders 10, 77\u201381 (1996).","journal-title":"Alzheimer disease and associated disorders"},{"key":"31756_CR31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.neurobiolaging.2008.05.010","volume":"31","author":"X He","year":"2010","unstructured":"He, X., Huang, Y., Li, B., Gong, C. X. & Schuchman, E. H. Deregulation of sphingolipid metabolism in Alzheimer\u2019s disease. Neurobiology of aging 31, 398\u2013408, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2008.05.010 (2010).","journal-title":"Neurobiology of aging"},{"key":"31756_CR32","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/j.1471-4159.1992.tb10994.x","volume":"59","author":"M Soderberg","year":"1992","unstructured":"Soderberg, M., Edlund, C., Alafuzoff, I., Kristensson, K. & Dallner, G. Lipid composition in different regions of the brain in Alzheimer\u2019s disease\/senile dementia of Alzheimer\u2019s type. Journal of neurochemistry 59, 1646\u20131653 (1992).","journal-title":"Journal of neurochemistry"},{"key":"31756_CR33","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.pharep.2015.12.008","volume":"68","author":"K Bienias","year":"2016","unstructured":"Bienias, K., Fiedorowicz, A., Sadowska, A., Prokopiuk, S. & Car, H. Regulation of sphingomyelin metabolism. Pharmacological reports: PR 68, 570\u2013581, https:\/\/doi.org\/10.1016\/j.pharep.2015.12.008 (2016).","journal-title":"Pharmacological reports: PR"},{"key":"31756_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF01001351","volume":"3","author":"AA Farooqui","year":"1988","unstructured":"Farooqui, A. A., Liss, L. & Horrocks, L. A. Neurochemical aspects of Alzheimer\u2019s disease: involvement of membrane phospholipids. Metabolic brain disease 3, 19\u201335 (1988).","journal-title":"Metabolic brain disease"},{"key":"31756_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/00005072-199907000-00008","volume":"58","author":"Z Guan","year":"1999","unstructured":"Guan, Z. et al. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. Journal of neuropathology and experimental neurology 58, 740\u2013747 (1999).","journal-title":"Journal of neuropathology and experimental neurology"},{"key":"31756_CR36","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1073\/pnas.89.5.1671","volume":"89","author":"RM Nitsch","year":"1992","unstructured":"Nitsch, R. M. et al. Evidence for a membrane defect in Alzheimer disease brain. Proceedings of the National Academy of Sciences of the United States of America 89, 1671\u20131675 (1992).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"31756_CR37","doi-asserted-by":"crossref","unstructured":"Han, X., D, M. H., McKeel, D. W. Jr., Kelley, J. & Morris, J. C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer\u2019s disease: potential role in disease pathogenesis. Journal of neurochemistry 82, 809\u2013818 (2002).","DOI":"10.1046\/j.1471-4159.2002.00997.x"},{"key":"31756_CR38","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00702-003-0007-9","volume":"110","author":"C Mulder","year":"2003","unstructured":"Mulder, C. et al. Decreased lysophosphatidylcholine\/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer\u2019s disease. J Neural Transm (Vienna) 110, 949\u2013955, https:\/\/doi.org\/10.1007\/s00702-003-0007-9 (2003).","journal-title":"J Neural Transm (Vienna)"},{"key":"31756_CR39","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.neurobiolaging.2004.02.016","volume":"25","author":"A Walter","year":"2004","unstructured":"Walter, A. et al. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiology of aging 25, 1299\u20131303, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2004.02.016 (2004).","journal-title":"Neurobiology of aging"},{"key":"31756_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","volume":"22","author":"M Maceyka","year":"2012","unstructured":"Maceyka, M., Harikumar, K. B., Milstien, S. & Spiegel, S. Sphingosine-1-phosphate signaling and its role in disease. Trends in cell biology 22, 50\u201360, https:\/\/doi.org\/10.1016\/j.tcb.2011.09.003 (2012).","journal-title":"Trends in cell biology"},{"key":"31756_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/2051-5960-2-12","volume":"2","author":"J Ceccom","year":"2014","unstructured":"Ceccom, J. et al. Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer\u2019s disease. Acta neuropathologica communications 2, 12, https:\/\/doi.org\/10.1186\/2051-5960-2-12 (2014).","journal-title":"Acta neuropathologica communications"},{"key":"31756_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/2051-5960-2-9","volume":"2","author":"TA Couttas","year":"2014","unstructured":"Couttas, T. A. et al. Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer\u2019s disease pathogenesis. Acta neuropathologica communications 2, 9, https:\/\/doi.org\/10.1186\/2051-5960-2-9 (2014).","journal-title":"Acta neuropathologica communications"},{"key":"31756_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/jcbfm.2012.174","volume":"33","author":"TA Cartwright","year":"2013","unstructured":"Cartwright, T. A., Campos, C. R., Cannon, R. E. & Miller, D. S. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 33, 381\u2013388, https:\/\/doi.org\/10.1038\/jcbfm.2012.174 (2013).","journal-title":"Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism"},{"key":"31756_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clineuro.2016.04.025","volume":"146","author":"L Castaneyra-Ruiz","year":"2016","unstructured":"Castaneyra-Ruiz, L. et al. Cerebrospinal fluid levels of tumor necrosis factor alpha and aquaporin 1 in patients with mild cognitive impairment and idiopathic normal pressure hydrocephalus. Clinical neurology and neurosurgery 146, 76\u201381, https:\/\/doi.org\/10.1016\/j.clineuro.2016.04.025 (2016).","journal-title":"Clinical neurology and neurosurgery"},{"key":"31756_CR45","first-page":"586","volume":"35","author":"L Sosvorova","year":"2014","unstructured":"Sosvorova, L. et al. Selected pro- and anti-inflammatory cytokines in cerebrospinal fluid in normal pressure hydrocephalus. Neuro endocrinology letters 35, 586\u2013593 (2014).","journal-title":"Neuro endocrinology letters"},{"key":"31756_CR46","doi-asserted-by":"publisher","first-page":"e91974","DOI":"10.1371\/journal.pone.0091974","volume":"9","author":"OT Pyykko","year":"2014","unstructured":"Pyykko, O. T. et al. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus. PloS one 9, e91974, https:\/\/doi.org\/10.1371\/journal.pone.0091974 (2014).","journal-title":"PloS one"},{"key":"31756_CR47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas","author":"S Kim","year":"2018","unstructured":"Kim, S. GBA1 deficiency negatively affects physiological \u03b1-synuclein tetramers and related multimers. PNAS. https:\/\/doi.org\/10.1073\/pnas (2018).","journal-title":"PNAS"},{"key":"31756_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2017.12.012","author":"F Zunke","year":"2017","unstructured":"Zunke, F. et al. Reversible Conformational Conversion of alpha-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron. https:\/\/doi.org\/10.1016\/j.neuron.2017.12.012 (2017).","journal-title":"Neuron"},{"key":"31756_CR49","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1021\/acs.analchem.5b04227","volume":"88","author":"M Boutin","year":"2016","unstructured":"Boutin, M., Sun, Y., Shacka, J. J. & Auray-Blais, C. Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease. Analytical chemistry 88, 1856\u20131863, https:\/\/doi.org\/10.1021\/acs.analchem.5b04227 (2016).","journal-title":"Analytical chemistry"},{"key":"31756_CR50","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","volume":"9","author":"B Dubois","year":"2010","unstructured":"Dubois, B. et al. Revising the definition of Alzheimer\u2019s disease: a new lexicon. The Lancet. Neurology 9, 1118\u20131127, https:\/\/doi.org\/10.1016\/S1474-4422(10)70223-4 (2010).","journal-title":"The Lancet. Neurology"},{"key":"31756_CR51","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/metabo5020389","volume":"5","author":"ZH Alshehry","year":"2015","unstructured":"Alshehry, Z. H. et al. An Efficient Single Phase Method for the Extraction of Plasma Lipids. Metabolites 5, 389\u2013403, https:\/\/doi.org\/10.3390\/metabo5020389 (2015).","journal-title":"Metabolites"},{"key":"31756_CR52","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1021\/bi00405a021","volume":"27","author":"B Domon","year":"1988","unstructured":"Domon, B. & Costello, C. E. Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry. Biochemistry 27, 1534\u20131543 (1988).","journal-title":"Biochemistry"},{"key":"31756_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/mas.1280120103","volume":"12","author":"J Adams","year":"1993","unstructured":"Adams, J. & Ann, Q. Structure determination of sphingolipids by mass spectrometry. Mass Spectrom Rev 12, 51\u201385 (1993).","journal-title":"Mass Spectrom Rev"},{"key":"31756_CR54","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nmeth.2551","volume":"10","author":"T Kind","year":"2013","unstructured":"Kind, T. et al. LipidBlast in silico tandem mass spectrometry database for lipid identification. Nature methods 10, 755\u2013758, https:\/\/doi.org\/10.1038\/nmeth.2551 (2013).","journal-title":"Nature methods"},{"issue":"Suppl 1","key":"31756_CR55","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/pmic.200700683","volume":"7","author":"NA Karp","year":"2007","unstructured":"Karp, N. A. & Lilley, K. S. Design and analysis issues in quantitative proteomics studies. Proteomics 7(Suppl 1), 42\u201350, https:\/\/doi.org\/10.1002\/pmic.200700683 (2007).","journal-title":"Proteomics"},{"key":"31756_CR56","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1021\/pr050084g","volume":"4","author":"NA Karp","year":"2005","unstructured":"Karp, N. A., Spencer, M., Lindsay, H., O\u2019Dell, K. & Lilley, K. S. Impact of replicate types on proteomic expression analysis. Journal of proteome research 4, 1867\u20131871, https:\/\/doi.org\/10.1021\/pr050084g (2005).","journal-title":"Journal of proteome research"},{"key":"31756_CR57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ymeth.2005.01.009","volume":"36","author":"AH Merrill Jr.","year":"2005","unstructured":"Merrill, A. H. Jr., Sullards, M. C., Allegood, J. C., Kelly, S. & Wang, E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36, 207\u2013224, https:\/\/doi.org\/10.1016\/j.ymeth.2005.01.009 (2005).","journal-title":"Methods"}],"updated-by":[{"DOI":"10.1038\/s41598-020-66184-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31756-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31756-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31756-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:24:17Z","timestamp":1671614657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31756-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["31756"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-31756-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-020-66184-6","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"14 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13639"}}